Tiago Marques

Executive

Chief Executive Officer

Insider activity · 24 months1 buy1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 1 saleJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 1 buy · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€22k

▼ Sales (1 ops.)

€714

Latest filing published 01 Dec 2025 for Pasithea Therapeutics Corp., €22k. Read the official filing

Filing timeline

BuySale

Tiago Marques

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Tiago Marques: trading record in brief

Tiago Marques, listed as chief executive, appears in our data through filings on Pasithea Therapeutics Corp. shares, published by SEC (Form 4). Over a trading history stretching from 20 December 2021 to 28 November 2025, the count stands at 6 filings.

Both buying and selling appear: 1 purchase worth €22k, against 1 sale worth €714. The net balance comes to €21k on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 4 share grants. So far in 2025, the count stands at 1 purchase and 1 sale.

The record was last updated on 1 December 2025 with an open-market purchase (€22k) in Pasithea Therapeutics Corp. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.